USP22 promotes resistance to EGFR-TKIs by preventing ubiquitination-mediated EGFR degradation in EGFR-mutant lung adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer letters"
DOI: 10.1016/j.canlet.2018.07.002
Abstract: As a newly discovered deubiquitinating enzyme, ubiquitin-specific protease 22 (USP22) is predictive of therapeutic outcomes in individual cancer patients. However, its clinical effects on malignancy and its roles in conferring resistance to EGFR-TKIs (epidermal growth… read more here.
Keywords: egfr; egfr mutant; resistance egfr; egfr tkis ... See more keywords
Aurora kinases shed light on resistance to EGFR inhibition in head and neck cancer
Sign Up to like & getrecommendations! Published in 2021 at "EBioMedicine"
DOI: 10.1016/j.ebiom.2021.103257
Abstract: Despite technological improvements in cancer diagnosis and treatment, the 5-year survival rate of head and neck squamous cell carcinoma (HNSCC) patients remains largely stagnant [1]. Recently, immunotherapy has been FDA approved for use in this… read more here.
Keywords: egfr; resistance egfr; hnscc; resistance ... See more keywords
Targeting nicotinamide N-methyltransferase overcomes resistance to EGFR-TKI in non-small cell lung cancer cells
Sign Up to like & getrecommendations! Published in 2022 at "Cell Death Discovery"
DOI: 10.1038/s41420-022-00966-x
Abstract: Activating mutations of epidermal growth factor receptor (EGFR) contributes to the progression of non-small cell lung cancer (NSCLC). EGFR tyrosine kinase inhibitor (TKI)-targeted therapy has become the standard treatment for NSCLC patients with EGFR-mutations. However,… read more here.
Keywords: tki; cell; resistance egfr; egfr tki ... See more keywords
Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2022 at "Nature communications"
DOI: 10.1038/s41467-022-29292-7
Abstract: Resistance to EGFR inhibitors (EGFRi) presents a major obstacle in treating non-small cell lung cancer (NSCLC). One of the most exciting new ways to find potential resistance markers involves running functional genetic screens, such as… read more here.
Keywords: cell lung; resistance; small cell; non small ... See more keywords
Molecular mechanism of acquired drug resistance in the EGFR‐TKI resistant cell line HCC827‐TR
Sign Up to like & getrecommendations! Published in 2020 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.13342
Abstract: The first‐line standard treatment of non‐small cell lung cancer (NSCLC) with EGFR mutation is EGFR‐tyrosine kinase inhibitors (TKIs). However, most patients will develop acquired resistance after 9–13 months. This study investigated novel molecular mechanisms of acquired… read more here.
Keywords: egfr; tki resistant; resistance egfr; line ... See more keywords
Targeting AKR1B1 inhibits glutathione de novo synthesis to overcome acquired resistance to EGFR-targeted therapy in lung cancer
Sign Up to like & getrecommendations! Published in 2021 at "Science Translational Medicine"
DOI: 10.1126/scitranslmed.abg6428
Abstract: Description AKR1B1 boosts glutathione de novo synthesis as a metabolic mechanism driving resistance to EGFR-targeted therapy in mouse models of lung cancer. An antidiabetic drug overcomes TKI resistance Resistance to epidermal growth factor receptor tyrosine… read more here.
Keywords: resistance; resistance egfr; lung cancer;
PO-132 Alpha5 beta1 integrin provides glioma cell resistance to EGFR tyrosine kinase inhibitors. role of membrane trafficking
Sign Up to like & getrecommendations! Published in 2018 at "ESMO Open"
DOI: 10.1136/esmoopen-2018-eacr25.173
Abstract: Introduction Overexpression of epidermal growth factor (EGFR) drives glioblastoma (GBM) cell invasion and tumour progression. EGFR has been a major therapeutic target in GBM. However, clinical trials were disappointing, and we are still missing molecular… read more here.
Keywords: gbm; cell; integrin; resistance egfr ... See more keywords
Hypoxia Induces Resistance to EGFR Inhibitors in Lung Cancer Cells via Upregulation of FGFR1 and the MAPK Pathway
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/0008-5472.can-20-1192
Abstract: Hypoxia-induced resistance to EGFR TKI is driven by overexpression of FGFR1 to sustain ERK signaling, where a subsequent combination of EGFR TKI with FGFR1 inhibitors or MEK inhibitors reverses this resistance. Development of resistance remains… read more here.
Keywords: hypoxia; resistance egfr; resistance; fgfr1 ... See more keywords
Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Research"
DOI: 10.1158/0008-5472.can-20-3555
Abstract: This study reports that stepwise acquisition of kinase inhibitor resistance in lung cancers driven by mutant EGFR comprises a nonmutational, reversible resister state. Lung cancers driven by mutant forms of EGFR invariably develop resistance to… read more here.
Keywords: host dependent; kinase; resistance egfr; resistance ... See more keywords
FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-0232
Abstract: Purpose: Recurrent and/or metastatic unresectable cutaneous squamous cell carcinomas (cSCCs) are treated with chemotherapy or radiotherapy, but have poor clinical responses. A limited response (up to 45% of cases) to EGFR-targeted therapies was observed in… read more here.
Keywords: resistance egfr; egfr targeted; resistance; egfr ... See more keywords
Abstract A142: Targeting FGFR to overcome EMT-related resistance in EGFR-mutated non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2018 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-17-a142
Abstract: Epithelial-to-mesenchymal transition (EMT) has been identified as a mechanism of both adaptive and acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) in in vitro models and clinical samples of EGFR-mutated non-small cell lung cancer (NSCLC).… read more here.
Keywords: egfr mutated; egfr; resistance egfr; resistance ... See more keywords